Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 3089-3094

  Magro, Margarita ^a   Mas, Vicente ^a   Chappell, Keith ^a,c   Vázquez, Mónica ^a   Cano, Olga ^a   Luque, Daniel ^b   Terrón, María C ^b   Melero, José A ^a   Palomo, Concepción ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HUMANS; IMMUNIZATION; MOLECULAR SEQUENCE DATA; PROTEIN STABILITY; RABBITS; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINIA VIRUS; VIRAL FUSION PROTEINS;

EID: 84857410882     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1115941109     Document Type: Article

References (32)

1. Nair H, et al. (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375:1545-1555.
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE (2005) Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749-1759. (Pubitemid 40570923)
3. Kim HW, et al. (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422-434.
4. Collins PL, Crowe JE (2007) Respiratory syncytial virus and metapneumovirus. Fields Virology (Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia), 5th Ed, pp 1601-1646.
5. Stott EJ, et al. (1987) Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 61:3855-3861. (Pubitemid 18011485)
6. Connors M, Collins PL, Firestone CY, Murphy BR (1991) Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 65:1634-1637.
7. Graham BS, Davis TH, Tang YW, Gruber WC (1993) Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virusspecific immune serum. Pediatr Res 34:167-172. (Pubitemid 23207201)
8. Prince GA, Hemming VG, Horswood RL, Chanock RM (1985) Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 3:193-206. (Pubitemid 16225057)
9. Hall CB, Walsh EE, Long CE, Schnabel KC (1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163:693-698.
10. Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:543-546. (Pubitemid 16120909)
11. Falsey AR, Walsh EE (1998) Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 177:463-466. (Pubitemid 28063776)
12. Groothuis JR, et al.; The Respiratory Syncytial Virus Immune Globulin Study Group (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329:1524-1530. (Pubitemid 23332437)
13. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531-537.
14. González-Reyes L, et al. (2001) Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 98:9859-9864. (Pubitemid 32769394)
15. Lamb RA (1993) Paramyxovirus fusion: A hypothesis for changes. Virology 197:1-11.
16. Lamb RA, Jardetzky TS (2007) Structural basis of viral invasion: Lessons from paramyxovirus F. Curr Opin Struct Biol 17:427-436. (Pubitemid 47451774)
17. Calder LJ, et al. (2000) Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271:122-131. (Pubitemid 30341521)
18. Magro M, Andreu D, Gómez-Puertas P, Melero JA, Palomo C (2010) Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol 84:7970-7982.
19. Sastre P, Melero JA, García-Barreno B, Palomo C (2005) Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. J Med Virol 76:248-255. (Pubitemid 40594011)
20. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS (2006) Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38-44. (Pubitemid 43053622)
21. Connolly SA, Leser GP, Yin HS, Jardetzky TS, Lamb RA (2006) Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc Natl Acad Sci USA 103:17903-17908. (Pubitemid 44852258)
22. Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME (2011) Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer. J Virol 85:3968-3977.
23. Ludwig K, et al. (2008) Electron cryomicroscopy reveals different F1+F2 protein States in intact parainfluenza virions. J Virol 82:3775-3781. (Pubitemid 351429952)
24. Sastre P, Melero JA, García-Barreno B, Palomo C (2004) Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities. Vaccine 23:435-443. (Pubitemid 39463026)
25. Delgado MF, et al. (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:34-41.
26. McLellan JS, Yang Y, Graham BS, Kwong PD (2011) Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796.
27. Swanson KA, et al. (2011) Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 108:9619-9624.
28. Zhao X, Singh M, Malashkevich VN, Kim PS (2000) Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci USA 97:14172-14177. (Pubitemid 32016549)
29. López JA, et al. (1998) Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 72:6922-6928. (Pubitemid 28324018)
30. Zhao X, Chen FP, Megaw AG, Sullender WM (2004) Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 190:1941-1946. (Pubitemid 39564699)
31. McLellan JS, et al. (2010) Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 17:248-250.
32. Toiron C, et al. (1996) Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein. Biopolymers 39:537-548.